Figure 1
Reversal of paclitaxel or vinblastine resistances by novel inhibitors of P-glycoprotein using metabolic viability assays. A2780ADR cells were treated in the presence of compounds 29, 34, 45 or verapamil with the indicated concentrations of chemotherapeutic. Panel A: circles, paclitaxel alone; squares, paclitaxel plus 25 µM compound 29; triangles, paclitaxel plus 25 µM compound 34; inverted triangles, paclitaxel plus 25 µM compound 45; stars, paclitaxel plus 25 µM P-gp substrate verapamil. Panel B: circles, vinblastine alone; squares, vinblastine plus 10 µM compound 29; triangles, vinblastine plus 10 µM compound 34; inverted triangles, vinblastine plus 10 µM compound 45; stars, vinblastine plus 10 µM P-gp substrate verapamil. Data represents the mean ± SD of 12 replicates from two independent experiments. Panel C: Chemical structures of novel P-gp inhibitors 29, 34 and 45. PTX, paclitaxel; VIN, vinblastine; VER, verapamil.
